Frier Levitt is featured in a Fierce Healthcare article titled, “PBMs Defend Business Practices — but Lawmakers Aren’t Convinced” by Noah Tong. The article covers a recent House Committee on Oversight and Accountability hearing, where lawmakers criticized abusive PBM practices. While shedding light on DIR fees, the article references Frier Levitt’s recent $22 million court judgment against CVS Caremark for New York Cancer & Blood Specialists (NYCBS). The article quotes Frier Levitt, stating, “Caremark began to assess fees on NYCBS if its patients did not adhere to taking oncology drugs prescribed to them, even if the continued use of these highly toxic medications posed health risks to the patients.” In this instance, the court deemed it was unlawful for Caremark to award DIR fees under this scenario.
Read the article here: https://www.fiercehealthcare.com/payers/pbms-defend-its-business-practices-lawmakers-arent-convinced
